

## **SUMMARY OF PRODUCT CHARACTERISTICS**

### **1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Orbeseal Dry Cow 2.6 g intramammary suspension for cattle

### **2. QUALITATIVE AND QUANTITATIVE COMPOSITION**

Each 4 g intramammary syringe contains:

**Active substance:**

Bismuth subnitrate, heavy 2.6 g  
(equivalent to Bismuth, heavy 1.858 g)

**Excipient(s):**

For the full list of excipients, see section 6.1.

### **3. PHARMACEUTICAL FORM**

Greyish white, smooth, unctuous intramammary suspension.

### **4. CLINICAL PARTICULARS**

#### **4.1 Target species**

Cattle (dairy cow at drying-off).

#### **4.2 Indications for use, specifying the target species**

Prevention of new intramammary infections throughout the dry period.

In cows considered likely to be free of sub-clinical mastitis, the veterinary medicinal product can be used on its own in dry cow management and mastitis control.

#### **4.3 Contraindications**

See section 4.7. Do not use the veterinary medicinal product alone in cows with sub-clinical mastitis at drying off. Do not use in cows with clinical mastitis at drying off.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

#### 4.4 Special warnings for each target species

Selection of cows for treatment with the veterinary medicinal product should be based on veterinary clinical judgement. Selection criteria may be based on the mastitis and cell count history of individual cows or recognised tests for the detection of subclinical mastitis or bacteriology sampling.

#### 4.5 Special precautions for use

##### Special precautions for safe use in the target species:

It is good practice to observe dry cows regularly for signs of clinical mastitis. If a sealed quarter develops clinical mastitis, the affected quarter should be stripped out manually before appropriate therapy is instituted.

To reduce the risk of contamination, do not immerse the syringe in water.

Use the syringe only once.

Since the veterinary medicinal product does not have antimicrobial activity, in order to minimize the risk of acute mastitis due to poor infusion technique and lack of hygiene (see section 4.6), it is crucial to follow the aseptic technique of administration described in section 4.9.

Do not administer any other intramammary product following administration of the product. In cows that may have sub-clinical mastitis, the veterinary medicinal product may be used following administration of a suitable dry cow antibiotic treatment to the infected quarter.

##### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

This veterinary medicinal product may cause skin and eye irritation.

Avoid contact with skin or eyes.

Should skin or eye contact occur, wash the affected area thoroughly with water.

If irritation persists, seek medical advice and show this label to the physician.

People with known hypersensitivity to bismuth salts should avoid contact with the veterinary medicinal product.

Wash hands after use.

##### Special precautions for the protection of the environment:

Not applicable.

#### 4.6 Adverse reactions (frequency and seriousness)

Cattle (dairy cow at drying-off).

Very rare (<1 animal / 10,000 animals treated, including isolated reports):	Acute mastitis <sup>1</sup> .
---	-------------------------------

<sup>1</sup>Primarily due to poor infusion technique and lack of hygiene. Please refer to sections 4.5 and 4.9 regarding the importance of aseptic technique.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also 'Contact details' section of the package leaflet.

#### **4.7 Use during pregnancy, lactation or lay**

##### Pregnancy:

The veterinary medicinal product is not absorbed following intramammary infusion.

Can be used in pregnancy. At calving, the seal may be ingested by the calf. Ingestion of the veterinary medicinal product by the calf is safe and produces no adverse effects.

##### Lactation:

Do not use during lactation. If accidentally used in a lactating cow, a small (up to 2-fold) transient rise in somatic cell count may be observed. In such an event, strip out the seal manually, no additional precautions are necessary.

#### **4.8 Interaction with other medicinal products and other forms of interaction**

In clinical trials, the compatibility of the veterinary medicinal product has only been shown with a cloxacillin-containing dry cow preparation. See also section 4.5 "Special precautions for safe use the target species".

#### **4.9 Amount(s) to be administered and administration route**

Intramammary use only.

Infuse the contents of one intramammary syringe of the veterinary medicinal product into each udder quarter immediately after the last milking of the lactation (at drying off.). Do not massage the teat or udder after infusion of the veterinary medicinal product.

Care must be taken not to introduce pathogens into the teat in order to reduce the risk of post-infusion mastitis.

It is essential that the teat is thoroughly cleaned and disinfected, with surgical spirit or alcohol-impregnated wipes. The teats should be wiped until the wipes are no longer visibly dirty. Teats should be allowed to dry prior to infusion. Infuse aseptically and take care to avoid contamination of the syringe nozzle. Following infusion it is advisable to use an appropriate teat dip or spray.

Under cold conditions the veterinary medicinal product may be warmed to room temperature in a warm environment, to aid syringeability.

#### **4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary**

Twice the recommended dose has been administered to cows with no clinical adverse effects.

#### **4.11 Withdrawal period(s)**

Meat and offal: Zero days.  
Milk: Zero hours.

### **5. PHARMACOLOGICAL PROPERTIES**

**Pharmacotherapeutic group:** Various products for teats and udder

**ATC Vet Code:** QG52X

#### **5.1 Pharmacodynamic properties**

Infusion of the veterinary medicinal product into each udder quarter produces a physical barrier against the entry of bacteria there by reducing the incidence of new intramammary infections during the dry period.

#### **5.2 Pharmacokinetic particulars**

Bismuth subnitrate is not absorbed from the mammary gland, but resides as a seal in the teat until physically removed (shown in cows with a dry period up to 100 days).

### **6. PHARMACEUTICAL PARTICULARS**

#### **6.1 List of excipients**

Liquid paraffin  
Aluminium Di Tri Stearate  
Silica, Colloidal Anhydrous

#### **6.2 Major Incompatibilities**

None known.

#### **6.3 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 5 years

#### **6.4 Special precautions for storage**

This veterinary medicinal product does not require any special storage conditions.

## **6.5 Nature and composition of immediate packaging**

A 4 g single dose low-density polyethylene intramammary syringe with a smooth, tapered hermetically sealed nozzle.  
Available in boxes of 24, 60 and plastic bucket of 120 or 144 syringes.  
Not all pack sizes may be marketed.

## **6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater.  
Any unused veterinary medicinal product or waste materials derived from such veterinary medicinal product should be disposed of in accordance with local requirements.

## **7. MARKETING AUTHORISATION HOLDER**

Zoetis UK Limited  
1st Floor, Birchwood Building  
Springfield Drive  
Leatherhead  
Surrey  
KT22 7LP

## **8. MARKETING AUTHORISATION NUMBER**

Vm 42058/5106

## **9. DATE OF FIRST AUTHORISATION**

25 June 2002

## **10. DATE OF REVISION OF THE TEXT**

August 2024

## **11. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

*Gavin Hall*  
Approved: 01 December 2024